Swissmedic has issued an urgent recall of several batches of the veterinary medicine Gonavet Veyx ad us. vet., an injectable solution intended for use in cattle, pigs, and horses. The affected batches include 24G253, 24B072, 24L029, and 23K022. This recall extends to the retail distribution level, providing transparency and addressing potential concerns for veterinarians and regulatory teams managing animal health treatments.
This announcement underscores Swissmedic’s commitment to ensuring the safety and efficacy of veterinary medicines available in Switzerland.
What changed?
The recall impacts batches of Gonavet Veyx ad us. vet. injectable solution, a widely used veterinary medicine. Swissmedic has determined a necessity for intervention due to undisclosed concerns linked to these specific production batches. The recall has been issued to maintain stringent quality and regulatory standards, ensuring animal welfare and protecting users from potential risks.
The recalled medicine is distributed for use in cattle, pigs, and horses, making this announcement relevant for livestock veterinarians, veterinary pharmacists, and those tasked with regulatory compliance in animal health products.
Which batches are affected?
Swissmedic highlights that the following batches are included in the recall:
- Batch 24G253
- Batch 24B072
- Batch 24L029
- Batch 23K022
All products belonging to these batches must be removed from retail distribution immediately. Regulatory or quality assurance personnel are advised to conduct inventory checks to ensure compliance with this directive.
What regulatory actions were taken?
Swissmedic’s decision to issue a batch recall demonstrates its proactive approach to safeguarding public health and animal welfare through stringent oversight of pharmaceutical products. This recall reflects adherence to legal obligations outlined in Swiss veterinary medicine regulations.
Stakeholders involved in the distribution and administration of Gonavet Veyx have been directly informed to facilitate rapid action. Swiss retail outlets must comply by ceasing sales of the affected batches and returning stock as per Swissmedic instructions.
Additional monitoring may follow to ensure the recall proceeds efficiently.
FAQ
Q1: Why is Gonavet Veyx being recalled?
A1: Swissmedic identified specific concerns related to the quality or safety of the listed batches. Although details remain undisclosed, the recall acts as a precautionary measure.
Q2: How should veterinary professionals handle affected stock?
A2: Veterinary clinics, pharmacists, or retail outlets must immediately cease distribution and return stock to the appropriate channels as instructed by Swissmedic.
Q3: Are other batches of Gonavet Veyx affected?
A3: No. The recall is limited to batches 24G253, 24B072, 24L029, and 23K022.
Conclusion
Swissmedic’s recall of Gonavet Veyx ad us. vet. emphasizes its responsibility to uphold safety in veterinary treatments. The affected batches pose undisclosed risks, requiring immediate removal from the retail level. Veterinary professionals must act promptly to ensure compliance with this directive.
Disclaimer
This information is intended for veterinary and regulatory professionals. It does not constitute legal advice or replace formal guidance from Swissmedic or other authorities.
Swissmedic Official Notice
For full information about the Swissmedic announcement, see the link below.